Converging GLP‑1 / tirzepatide / orforglipron postmarket safety signals
Key Questions
What is Foundayo and how was it approved?
Foundayo is an oral GLP-1 pill (orforglipron) approved by the FDA for weight loss, with a record-fast 50-day review under CNPV. It requires titration up to 17.2mg and carries boxed warnings for thyroid tumors, along with risks of pancreatitis, GI issues, kidney problems, hypoglycemia, and hypersensitivity.
What risks are associated with Foundayo (orforglipron)?
Foundayo has potential serious side effects including pancreatitis, low blood glucose, gallbladder disease, and severe hypersensitivity reactions like anaphylaxis. The package insert highlights risks such as thyroid C-cell tumors based on animal studies.
Why did the FDA warn Novo Nordisk?
The FDA issued a warning letter to Novo Nordisk for failing to report required postmarketing adverse events for semaglutide, including deaths and suicidality. This involved unreported serious AEs that should have been submitted promptly.
What are the FDA warning letters about unapproved GLP-1 drugs?
The FDA sent warning letters to marketers of unapproved injectable GLP-1/GIP products like those from Prime Sciences and Lovega, citing risks such as bloodstream infections from poor manufacturing. Consumers should avoid these unapproved alternatives.
What is the MHRA investigating with semaglutide?
The UK's MHRA is probing possible side effects of semaglutide, specifically cases of acute pancreatitis linked to GLP-1 receptor agonists. This follows reports prompting a study into serious adverse events.
Are compounded GLP-1 alternatives safe?
Compounded GLP-1 alternatives carry significant risks due to lack of FDA approval and oversight, with doctors warning of potential contamination and dosing issues. Official guidance emphasizes avoiding them in favor of approved products.
What monitoring is recommended for GLP-1 drugs?
Users should monitor for adverse events via AEMS and MHRA systems, watching for signs of pancreatitis, hypersensitivity, or other risks. Report any issues and stick to approved formulations.
How does Novo Nordisk respond to Lilly's orforglipron approval?
Novo Nordisk highlighted semaglutide's established edge post-FDA clearance of Lilly's orforglipron, amid ongoing safety scrutiny. They continue promoting their approved products despite reporting lapses.
FDA approves Lilly Foundayo orforglipron oral pill (50-day CNPV, boxed thyroid tumors, pancreatitis/GI/kidney/hypo/hypersensitivity risks, titration to 17.2mg); FDA warns Novo unreported semaglutide AEs (deaths/suicidality) and issues letters to unapproved injectable GLP-1/GIP marketers (Prime Sciences/Lovega, bloodstream risks); MHRA semaglutide pancreatitis probe; compounded alts risks emphasized. Avoid compounds/unapproved; monitor AEMS/MHRA.